-
1
Head and neck cancer (HNC) is the seventh most prevalent cancer globally, with over 660,000 new cases and 325,000 deaths annually.
-
2
Chemoradiotherapy is commonly used for advanced HNC, but it has a higher incidence of sensorineural hearing loss (SNHL) compared to radiotherapy alone.
-
3
Studies indicate that 82.5% of HNC patients undergoing chemoradiotherapy experience SNHL, compared to 25.7% with radiotherapy.
-
4
This systematic review aims to compare the prevalence of SNHL in HNC patients receiving chemoradiotherapy versus those receiving radiotherapy.
-
5
The review includes studies published from 2010 to 2025, focusing on methodological quality and specific reporting of SNHL in HNC patients.
